{"id":"NCT03952806","sponsor":"Biohaven Pharmaceuticals, Inc.","briefTitle":"Study of BHV-3241 in Participants With Multiple System Atrophy","officialTitle":"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-07-29","primaryCompletion":"2021-07-29","completion":"2022-06-30","firstPosted":"2019-05-16","resultsPosted":"2023-09-29","lastUpdate":"2023-09-29"},"enrollment":421,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple System Atrophy"],"interventions":[{"type":"DRUG","name":"Verdiperstat","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Verdiperstat","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy of verdiperstat (BHV-3241) versus placebo in participants with Multiple System Atrophy","primaryOutcome":{"measure":"Change From Baseline in the Modified UMSARS Score at Week 48","timeFrame":"Baseline and Week 48","effectByArm":[{"arm":"Verdiperstat - Randomization Phase","deltaMin":5.2,"sd":null},{"arm":"Placebo - Randomization Phase","deltaMin":4.85,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4656"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":48,"countries":["United States","Austria","France","Germany","Italy","United Kingdom"]},"refs":{"pmids":["34115419"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":44,"n":168},"commonTop":["Urinary tract infection","Fall","Headache","Dizziness","Constipation"]}}